A. Gomez-Cadena

Discipline

Histoire, Philosophie et Sociologie des sciences (1)

Type de document

Articles (9) Recensions (2)

Co-auteur

Date

Source

Mot-clé

Cells (7) Cancer (7) cancer (6) Cancer (6) Human beings (6) Treatment (5) Diseases (5) Mice (5) Diseases (5) immunité (4) T cells (4) Immunity (4) Immune response (4) Animals (4) thérapie (3) spectacle (3) modèle (3) système immunitaire (3) allergie (3) effet (3) cytotoxicité (3) Immune system (3) Tumors--Growth (3) Therapeutics (3) Population (3) Patients (3) Melanoma (3) Functions (3) Expression (3) Example (3)

Documents écrit par A. Gomez-Cadena (9) | parle de A. Gomez-Cadena (0)

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.
G. Ercolano et al. (5 mai 2021)
Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment.
A. Gomez-Cadena et al.
Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment.
A. Gomez-Cadena et al. (18 mai 2020)
An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma.
P. Lasso et al. (2020)
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
B. Salomé et al. (26 nov. 2019)
Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping.
S. Trabanelli et al.
Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth.
P. Lasso et al. (2018)
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
S. Trabanelli et al. (19 sept. 2017)
Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model.
A. Gomez-Cadena et al. (2016)